Bacopa monnieri / P450 Cancer Research Results

BM, Bacopa monnieri: Click to Expand ⟱
Features:

Bacopa monnieri — a medicinal botanical herb, also called Brahmi, typically used as a standardized oral extract enriched in bacosides, which are dammarane-type triterpenoid saponins. Its formal classification is a phytotherapeutic botanical / dietary supplement rather than an approved anticancer drug. Standard abbreviation: BM. The source is the aerial herb of Bacopa monnieri, a traditional Ayurvedic plant. Mechanistically, BM is best supported as a neurocognitive and cytoprotective adaptogenic extract; its anticancer activity is real but remains preclinical, heterogeneous, and often driven by isolated fractions or bacopasides rather than routine oral human exposure.

Primary mechanisms (ranked):

  1. Modulation of intrinsic apoptosis and cell-cycle arrest in cancer models
  2. Aquaporin-1 linked antitumor effects of bacopaside fractions, including reduced proliferation, migration, and angiogenic behavior
  3. Anti-inflammatory signaling with suppression of NF-κB-linked survival programs
  4. Context-dependent modulation of PI3K/AKT and MAPK stress-survival signaling
  5. Redox modulation: antioxidant / NRF2-linked cytoprotection in normal tissues, but possible pro-apoptotic oxidative stress at higher in-vitro tumor doses

Bioavailability / PK relevance: Oral BM extracts are usually standardized to bacosides, but bacosides have limited aqueous solubility and modest systemic exposure; in-vivo metabolism to aglycones / downstream metabolites likely matters. This creates a delivery constraint for oncology because many direct tumor effects are reported at micromolar in-vitro concentrations or with enriched fractions not clearly achievable after routine oral supplementation.

In-vitro vs systemic exposure relevance: Common anticancer in-vitro concentrations likely exceed typical oral systemic exposure. By contrast, cognition-related effects appear compatible with chronic low-level oral exposure and adaptive signaling over weeks rather than acute high plasma peaks.

Clinical evidence status: Small human RCT evidence exists for cognition / stress-related outcomes. Dementia / AD evidence remains inconclusive and low-certainty. Oncology evidence is preclinical only; there is no established clinical anticancer role.

Key Active Compounds
  Bacosides (especially bacoside A and B)
  Brahmin
  Hersaponin
  Betulinic acid
  Steroidal saponins

AD Pathways:
  ↓ Aβ accumulation
  ↓ Tau hyperphosphorylation
  ↓ Pro-inflammatory cytokines (e.g., IL-1β, TNF-α, IL-6)
  ↑ Acetylcholine levels	Inhibits AChE,
  Strong antioxidant activity	↓ ROS, ↑ SOD, ↑ catalase, and ↑ GSH levels.

Potential Anticancer Mechanisms
  Reduces oxidative stress
  Inhibits NF-κB and COX-2
  Anti-angiogenic
whole-extract Bacopa monnieri effects from purified bacopaside I / II mechanisms; this distinction matters because the more specific anticancer mechanisms are often fraction-specific.

Bacopa monnieri mechanistic pathway map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Intrinsic apoptosis and cell-cycle control ↑ apoptosis; ↓ proliferation; G0/G1 or G2/M arrest (model-dependent) ↔ / cytoprotective R/G Tumor growth restraint Most reproducible cancer-facing effect across BM fractions and bacopasides; strength depends strongly on extract composition and concentration.
2 Aquaporin-1 axis ↓ proliferation; ↓ migration; ↓ invasion / angiogenic behavior ↔ R/G Membrane transport-linked antitumor effect This is one of the more specific mechanistic signals for bacopaside I / II, especially in colorectal and endothelial models; relevance is fraction-specific rather than clearly whole-extract universal.
3 NF-κB inflammatory survival signaling ↓ ↓ R/G Anti-inflammatory and anti-survival shift Likely contributes more confidently to normal-tissue neuroprotection than to a clinically useful direct anticancer effect.
4 PI3K/AKT and MAPK stress-survival signaling ↓ AKT; ERK/JNK/p38 modulation (context-dependent) ↔ / adaptive R/G Reduced survival signaling Reported in several models, but not yet a defining or standardized BM hallmark across tumor systems.
5 Mitochondrial ROS increase and apoptotic stress ↑ ROS (high concentration only); ↑ mitochondrial apoptosis ↓ oxidative injury P/R Redox bifurcation Important duality: normal tissues trend antioxidant, while some tumor models show pro-apoptotic oxidative stress only at higher exposures.
6 NRF2-linked antioxidant defense ↔ / ↑ (context-dependent) ↑ R/G Cytoprotection Central for neuroprotection and normal-cell antioxidant effects; in cancer this could be neutral or potentially counter-therapeutic depending on context, so it is not ranked as a core anticancer mechanism.
7 Angiogenesis and endothelial remodeling ↓ ↔ G Reduced vascular support Evidence is tied mainly to AQP1-active bacopaside work and endothelial assays rather than robust human translational data.
8 HIF-1α hypoxia adaptation ↓ (model-dependent) ↔ G Reduced hypoxic adaptation Secondary / contextual axis with limited direct evidence compared with apoptosis and AQP1-linked effects.
9 Chemosensitization or radiosensitization ↔ (insufficient evidence) ↔ G Not established No convincing clinical translation yet for use as a cancer sensitizer.
10 Clinical Translation Constraint ↓ ↓ — Exposure and standardization limitation Main constraints are extract heterogeneity, fraction-specific mechanisms, uncertain human tumor exposure, and lack of oncology trials.

TSF legend: P: 0–30 min
R: 30 min–3 hr
G: >3 hr



Bacopa monnieri (BM; Brahmi) — standardized extracts (typically 20–55% bacosides) studied in cognitive aging, MCI, and stress-related impairment. Mechanistically a neuroprotective adaptogen with antioxidant, anti-inflammatory, and synaptic plasticity–modulating effects.

Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (↑ NRF2-linked antioxidant enzymes; ↓ lipid peroxidation)
2) ↓ Neuroinflammation (↓ NF-κB; ↓ TNF-α / IL-1β in models)
3) ↑ Synaptic plasticity signaling (↑ BDNF/CREB; dendritic spine density in models)
4) ↓ Aβ aggregation / toxicity (preclinical emphasis)
5) Cholinergic modulation (↑ acetylcholine tone; acetylcholinesterase modulation)

Bioavailability / PK relevance: Orally bioavailable extracts cross the BBB at low concentrations; chronic dosing appears necessary for measurable cognitive benefit (weeks). Plasma levels modest; effects likely cumulative/adaptive rather than acute pharmacologic spikes.

Clinical evidence status: Multiple small RCTs show modest improvements in memory acquisition and processing speed in older adults and MCI; not disease-modifying approval for AD.

Bacopa monnieri — AD / Neurodegeneration Pathway Map

Rank Pathway / Axis Cells TSF Primary Effect Notes / Interpretation
1 ROS / Oxidative stress ↓ P/R Reduced neuronal oxidative burden Consistent antioxidant activity; decreases lipid peroxidation and improves endogenous antioxidant enzyme activity.
2 NRF2 axis ↑ R/G Stress-defense gene upregulation Supports increased SOD, catalase, glutathione enzymes; central to neuroprotection.
3 Neuroinflammation (NF-κB, cytokines) ↓ R/G Reduced microglial inflammatory signaling Important in slowing neurodegenerative progression in models.
4 BDNF / CREB signaling ↑ G Synaptic plasticity enhancement Linked to improved memory acquisition in animal and human cognitive studies.
5 Aβ aggregation / toxicity ↓ (preclinical) G Reduced amyloid-associated damage Shown in animal and cell models; human biomarker confirmation limited.
6 Cholinergic signaling ↑ tone (context-dependent) R/G Improved neurotransmission Modest acetylcholinesterase modulation and increased acetylcholine availability reported.
7 Mitochondrial function ↑ R/G Improved bioenergetic resilience Often secondary to reduced ROS and inflammation.
8 Ca²⁺ homeostasis ↔ / stabilized P/R Excitotoxic buffering Indirect stabilization through antioxidant and mitochondrial support.
9 Clinical Translation Constraint ↓ (constraint) — Modest effect size Benefits typically require ≥8–12 weeks; magnitude modest; not disease-modifying therapy.

TSF legend:
P: 0–30 min (direct antioxidant interactions)
R: 30 min–3 hr (acute signaling modulation)
G: >3 hr (gene regulation, synaptic adaptation)
P450, cytochrome P450 (CYP) family: Click to Expand ⟱
Source:
Type:
The cytochrome P450 (CYP) family includes many isoenzymes that play key roles in metabolizing endogenous substances (like hormones) and xenobiotics (including drugs and toxins). Changes in the expression of these enzymes in various cancers can affect carcinogen activation, drug metabolism, and overall tumor biology, influencing both cancer risk and prognosis.

CYP1B1
– Frequently overexpressed in several cancers including breast, ovarian, prostate, and colorectal cancers.
– Its expression is often low in normal tissues, making it a potential target for selective cancer therapies.

2. CYP3A4 and CYP3A5
These enzymes are highly expressed in the liver, but their expression is also observed in extrahepatic tissues.
– In cancer, CYP3A enzymes can be variably expressed; for instance, CYP3A4 may be upregulated in some liver cancers but downregulated in others.

3. CYP2E1
– CYP2E1 is expressed in the liver and extrahepatic tissues.
– Elevated CYP2E1 activity can lead to increased production of reactive oxygen species (ROS), contributing to DNA damage and cancer progression.

4. CYP19A1 (Aromatase)
– Aromatase converts androgens to estrogens and is expressed in adipose tissue as well as in certain tumors such as breast cancer.
– Its local expression in breast tumors can increase estrogen levels, promoting hormone-dependent tumor growth.

5. CYP2C Family (e.g., CYP2C8, CYP2C9, CYP2C19)
– These enzymes are involved in metabolizing various drugs and are expressed in the liver and intestines.
– Their expression levels can be altered in different tumor types, potentially affecting drug metabolism.

CYP450 enzymes are a large family with diverse roles in cancer biology.
• Their expression in cancers (e.g., CYP1B1, CYP3A4/5, CYP2E1, CYP19A1) has been linked to both the development and progression of tumors, as well as influencing responses to therapy.
Scientific Papers found: Click to Expand⟱
5480- BM,    Inhibition of Human Cytochrome P450 Enzymes by Bacopa monnieri Standardized Extract and Constituents
- Human, Nor, NA
P450↓, CYP3A4↓, CYP2C9↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

CYP3A4↓, 1,  

Drug Metabolism & Resistance ⓘ

CYP2C9↓, 1,   P450↓, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: P450, cytochrome P450 (CYP) family
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:339  Target#:1061  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page